Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study

BACKGROUND: Somatostatin analogs (SSAs) are the mainstay of neuroendocrine tumor (NET) treatment. Biliary stone disease is reported as a common side effect of SSAs, with a frequency ranging from 10% to 63%. Studies on SSA‐treated patients for acromegaly report an increased incidence of biliary stone...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Brighi, Nicole, Panzuto, Francesco, Modica, Roberta, Gelsomino, Fabio, Albertelli, Manuela, Pusceddu, Sara, Massironi, Sara, Lamberti, Giuseppe, Rinzivillo, Maria, Faggiano, Antongiulio, Spallanzani, Andrea, Ferone, Diego, Prinzi, Natalie, Rossi, Roberta Elisa, Annibale, Bruno, Colao, Anna Maria, Campana, Davide
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2019
Matèries:
Hepatobiliary
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066710/
https://ncbi.nlm.nih.gov/pubmed/32162819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0403
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars